Lidija Antunovic
Deputy director
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (13)
Year:
2026
IntroductionAccurate staging at diagnosis is essential for optimizing treatment strategies and prognosis in early breast cancer (EBC). [18F]FDG positron emission tomography/magnetic resonance imaging (PET/MRI) is a hybrid imaging modality that enables simultaneous evaluation of locoregional disease and metastatic spread. This study assessed the impact of [18F]FDG PET/MRI on treatment planning in patients with EBC.MethodsThis unplanned sub-study derives from a prospective, interventional, single-arm clinical trial (SNB vs PET/MRI 2) conducted at San Raffaele University Hospital (Milan) between July 2020 and April 2024 (NCT04829643). Patients with EBC scheduled for primary surgery underwent additional preoperative [18F]FDG PET/MRI. The primary endpoint was the proportion of patients whose treatment strategy was modified based on PET/MRI findings. The secondary endpoint was the performance of PET/MRI in detecting multifocal breast cancer compared with standard imaging.ResultsA total of 264 patients, including five bilateral cases, were analyzed. [18F]FDG PET/MRI led to treatment plan modifications in 30.7% of patients. Surgical approach was altered in 23.9%, while 4.9% received primary systemic therapy and 1.9% were referred for systemic therapy alone. PET/MRI showed a sensitivity of 61.7%, specificity of 84.9%, positive predictive value (PPV) of 49.1%, and negative predictive value (NPV) of 90.4% for multifocal disease detection. When combined with standard imaging, specificity and PPV increased to 96.0% and 63.6%, respectively (p=0.001). Multifocal tumors detected by PET/MRI accounted for 15.2% of the cohort.Conclusions[18F]FDG PET/MRI significantly influences treatment decisions in EBC, modifying management in nearly one-third of patients. However, its moderate diagnostic accuracy warrants caution to prevent overtreatment.
Year:
2026
Background/objectives: Pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer (BC) is a solid indicator of favourable prognosis, potentially also being useful for more conservative patient management. We aim to explore the potential of [18F]FDG PET/CT as a non-invasive method to predict response to NAC. Methods: In this prospective, observational cohort study, we enrolled BC patient candidates for NAC who underwent baseline and preoperative [18F]FDG PET/CT. NAC response was determined using final histopathology. PET images were assessed qualitatively and semi-quantitatively, and the findings correlated with NAC response. Results: In total, 133 BC patients were included. The visual analysis of preoperative PET/CT detected residual disease (RD) with high specificity (>93%) and moderate sensitivity, based on pCR/RD classification and RCB index. Semiquantitative measures (SUVmax, TBR) were significantly higher in non-responders across the classification methods (p < 0.001 for all). Conclusions: These findings highlight the potential of preoperative [18F]FDG PET/CT as a complementary tool for identifying excellent responders to NAC across BC subtypes or response criteria. This could inform personalised treatment and potentially allow for surgery to be omitted in selected patients.
Year:
2025
Year:
2025
Background Although many well-known factors affect the maximum standardized uptake value (SUVmax), it remains the most requested and used parameter, especially among clinicians, despite other parameters, such as the standardized uptake value corrected for lean body mass and the metabolic tumor volume, being proven to be less sensitive to the same factors, more robust, and eventually more informative. This study intends to provide robust evidence regarding the diagnostic and prognostic value of SUVmax in a large cohort of subjects with suspected malignant lung nodules imaged by [ 18 F]FDG PET/CT. Materials and methods We performed a retrospective analysis of patients with suspected/confirmed primary lung tumours undergoing [18F]FDG PET/CT. The sample size was 567 patients. Demographics, imaging, surgical, histological, and follow-up data were collected. SUVmax was analysed according to histology, stage, scanner, and outcome. The impact on measured values of different reconstruction protocols was assessed. All potential predictors of patients’ outcome were assessed. Results 91% cases were primary lung tumours. Lung benign nodules or metastases accounted for 5% and 4% of cases. Most patients presented with adenocarcinoma (70%) and stage I disease (51%); 144 patients relapsed and 55 died. SUVmax failed to effectively differentiate benign lesions from primary tumours or metastases. Stage I patients presented lower SUVmax. SUVmax significantly correlated with patient weight, injected [ 18 F]FDG activity, and lesion size and differed between reconstructions’ protocols. Survival analyses revealed no independent prognostic significance for SUVmax in progression-free after adjusting for other variables. SUVmax correlated with overall survival, disease stage and tumour histotype. Conclusion Our study confirms that SUVmax, though widely employed, present relevant limitations in discriminating between benign lesion and lung cancer, in classifying cancer histotypes, and in predicting patient outcomes independently. Known influencing factors significantly impact on numerical values, thus SUV values should be regarded with caution in clinical practice.
Year:
2024
Background: Recently, radiomics has emerged as a possible image-derived biomarker, predominantly stemming from retrospective analyses. We aimed to prospectively assess the predictive role of [18F]FDG-PET radiomics in breast cancer (BC). Methods: Patients affected by stage I–III BC eligible for neoadjuvant chemotherapy (NAC) staged with [18F]FDG-PET/CT were prospectively enrolled. The pathological response to NAC was assessed on surgical specimens. From each primary breast lesion, we extracted radiomic PET features and their predictive role with respect to pCR was assessed. Uni- and multivariate statistics were used for inference; principal component analysis (PCA) was used for dimensionality reduction. Results: We analysed 93 patients (53 HER2+ and 40 triple-negative (TNBC)). pCR was achieved in 44/93 cases (24/53 HER2+ and 20/40 TNBC). Age, molecular subtype, Ki67 percent, and stage could not predict pCR in multivariate analysis. In univariate analysis, 10 radiomic indices resulted in p < 0.1. We found that 3/22 radiomic principal components were discriminative for pCR. Using a cross-validation approach, radiomic principal components failed to discriminate pCR groups but predicted the stage (mean accuracy = 0.79 ± 0.08). Conclusions: This study shows the potential of PET radiomics for staging purposes in BC; the possible role of radiomics in predicting the pCR response to NAC in BC needs to be further investigated.
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (19)
Sofia Carrilho Vaz
Specialist in Nuclear Medicine
Champalimaud Foundation
Armando Santoro
Professore
Humanitas University
Federico Pessina
Full Professor
IRCCS Humanitas Research Hospital
daoud rahal
head of biopsy and interventional pathology section
IRCCS Humanitas Research Hospital
Arturo Chiti
Director
Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia
Lioe-Fee de Geus-Oei
Leiden University Medical Center
Maria Picchio
Associate Professor
Università Vita Salute San Raffaele
Martina Sollini
Associate Professor in Diagnostic Imaging and Radiotherapy
Vita-Salute San Raffaele University
ORESTE GENTILINI
Associate Professor
Vita-Salute San Raffaele University
Fabrizia Gelardi
Vita-Salute San Raffaele University
Luca Licata
Ospedale San Raffaele
Felix M. Mottaghy
Head of department
RWTH Aachen University
Ludovica Pitoni
Clinica Universidad de Navarra
Rita De Sanctis
Humanitas University
Patrizia Vizza
Università degli Studi di Roma Tor Vergata Facoltà di Medicina e Chirurgia
Giampaolo Bianchini
Head Breast Cancer Group
IRCCS Ospedale San Raffaele
Margarita Kirienko
Fondazione IRCCS Istituto Nazionale dei Tumori
ALESSIA ARTESANI
Assistant Professor
Humanitas University
Rosa Di Micco
Breast Surgeon
Ospedale San Raffaele
Make your next move.
Prepare your application
Review drafts before you send them.